Masimo's Wearable Thermometer Scores FDA Approval For Prescription, OTC Use

• Masimo (NASDAQ: MASI) has announced that Radius Tº, a wearable, wireless thermometer, has received FDA 510(k) clearance for both prescription and over-the-counter (OTC) use on patients and consumers five years and older.

• With continuous temperature measurements and Bluetooth connectivity, Radius Tº automates remote, ongoing body temperature status for clinicians through its paired connection to a Masimo patient monitoring or telehealth solution and for consumers through the Masimo Radius Tº smartphone application.

• For prescription use, Radius Tº is compatible with both the Root Patient Monitoring and Connectivity Hub and the Rad-97 patient monitor for use in the hospital, as part of the Masimo Hospital Automation platform.

• Price Action: MASI shares are down 1.27% at $237 during the market session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity

• Agios Pharma Files US Application For Mitapivat In PK Deficiency

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.